Evaluation treatment planning system for oropharyngeal cancer patient using machine learning.

Oropharyngeal cancer (OPC) comprises a group of various malignant tumours that grow in the throat, larynx, mouth, sinuses, and nose. THE RESEARCH AIMS: to investigate the performance of the OPC VMAT model by comparison to clinical plans in terms of dosimetric parameters and normal tissue complication probabilities. PURPOSE: Tune the model which at least matches the performance of clinical created photon treatment plans and analyse and find the most appropriate strategic plan scheme for OPC. METHODS AND MATERIALS: The machine learning (ML) plans are compared to the reference plans (clinical plans) based on dose constraints and target coverage. VMAT oropharynx ML model of Raystation development 11B version (non-clinical) was used. A model was trained by using different modalities. A different strategy of machine learning and clinical plans was performed for five patients. The dose Prescribed for OPC is 70 Gy, 2 Gy per fraction (2Gy/Fx). The PTV was derived for the primary tumour and secondary tumour, PTV+7000 cGy and PTV_5425 cGy volumetric modulated arc therapy (VMAT) were used with beams performing a full 360° rotation around the single isocenter. RESULTS: Organs at risk were observed that the volume of L-Eye in clinical plan (AF) for the case1 treatment planning could be successfully used ensuring efficiency and lower than MLVMAT and MLVMAT-org plans were 372 cGy, 697 cGy and 667 cGy respectively, while showed case2, case3, case4 and case5 are better to protect the critical organs in ML plan compare with a clinical plan. DHI for the PTV-7000 and PTV-5425 is between 1 and 1.34, While DCI for PTV-7000 and PTV-5425 is between 0.98 and 1.

Long-Term Patient-Reported Outcomes After Surgery for Superior Canal Dehiscence Syndrome.

OBJECTIVE: Evaluate the long-term patient-reported outcomes of surgery for superior canal dehiscence syndrome (SCDS). STUDY DESIGN: Cross-sectional survey. SETTING: Tertiary referral center. PATIENTS: Adults who have undergone surgery for SCDS with at least 1 year since surgery. MAIN OUTCOME MEASURE(S): Primary outcome: change in symptoms that led to surgery. SECONDARY OUTCOMES: change in 11 SCDS-associated symptoms, change in psychosocial metrics, and willingness to recommend surgery to friends with SCDS. RESULTS: Ninety-three (43%) respondents completed the survey with mean (SD) time since surgery of 5.3 (3.6) years. Ninety-five percent of respondents reported the symptoms that led them to have surgery were "somewhat better," "much better," or "completely cured." Those with unilateral symptoms were more likely to report improvement than those with bilateral symptoms. There was no difference between those with short (1-5 yr) versus long (5-20 yr) follow-up. Each of the SCDS-associated symptoms showed significant improvement. The largest improvements were for autophony, pulsatile tinnitus, audible bodily sounds, and sensitivity to loud sound. Headaches, imbalance, dizziness, and brain fog showed the least improvements. Most patients reported improvements in quality of life, mood, and ability to function at work and socially. Ninety-five percent of patients would recommend SCDS surgery. CONCLUSIONS: Respondents demonstrated durable improvements in the symptoms that led them to have surgery. Auditory symptoms had the greatest improvements. Headaches, imbalance, dizziness, and brain fog showed the least improvements. Nearly, all patients would recommend SCDS surgery to others. These results can be used to counsel patients regarding the lasting benefits of surgery for SCDS.